Immuno-Oncology Outlook: Bavencio Leads PD-1/L1 Pack In Ovarian Cancer
Executive Summary
Merck KGaA/Pfizer's Bavencio is likely to be the first checkpoint inhibitor to gain approval in ovarian cancer but Roche's Tecentriq is hot on its heels. The ovarian cancer pipeline boasts seven other late-stage drugs, including antibody-drug conjugates and small molecules, that are ready to ramp up competition on the market.
You may also be interested in...
Asia Deal Watch: Otsuka Gets Japanese Rights To Perception’s Mood Disorder Candidate
Plus deals involving I-Mab/Complix, Lupin/Endoceutics, Genome & Co/Pfizer/Merck KGaA, Genome & Co/Debiopharm, Exelixis/WuXi, Intas/Foresee, Wugen/Alpha Biosciences
Ovarian Cancer Pipeline Review: Sponsors Plan Frontline Punch, Smart Combinations
Combination studies of drugs for ovarian cancer have heavy focus on PARP, PD-1/L1 and VEGF mechanisms.
Merck KGAA/Pfizer's Anti-PD-L1 Bavencio Loses An Opportunity In Ovarian Cancer
PD-1/L1 inhibitors are eagerly awaited in ovarian cancer, but the combination of Bavencio with chemotherapy doesn't work well in platinum-resistant disease.